Macquarie Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Macquarie Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,992	Closed	-$200K	–	2064
2022 Q3	$200K	Sell	5,992 -2,163	-27%	-$40.2K	﹤0.01%	1623
2022 Q2	$34K	Hold	8,155	–	–	﹤0.01%	2152
2022 Q1	$94	Hold	8,155	–	–	﹤0.01%	1971
2021 Q4	$81K	Buy	8,155 +464	+6%	+$5.21K	﹤0.01%	2003
2021 Q3	$100K	Buy	7,691 +5,761	+298%	+$88K	﹤0.01%	1986
2021 Q2	$38K	Buy	1,930 +1,463	+313%	+$30.4K	﹤0.01%	2218
2021 Q1	$10K	Sell	467 -222	-32%	-$6.44K	﹤0.01%	2392
2020 Q4	$20K	Hold	689	–	–	﹤0.01%	2221
2020 Q3	$15K	Hold	689	–	–	﹤0.01%	2224
2020 Q2	$15K	Buy	+689	New	+$13.4K	﹤0.01%	2240
2018 Q1	–	Sell	-300	Closed	-$9K	–	2337
2017 Q4	$9K	Buy	+300	New	+$7.93K	﹤0.01%	2280

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Macquarie Group's RYTM Position: Q4 2022 in Review

Macquarie Group sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2022, closing a stake of 5,992 shares — an estimated $200K sold.

Macquarie Group first reported a position in RYTM in Q4 2017 and held it in 11 quarters. The position peaked at $200K in Q3 2022. 115 funds tracked by Wall St. Rank hold RYTM as of Q4 2022.

Macquarie Group reported no remaining Rhythm Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 5,992 Rhythm Pharmaceuticals shares in Q4 2022, an estimated $200K.
Macquarie Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 11 quarters.
Macquarie Group's Rhythm Pharmaceuticals position peaked at $200K in Q3 2022.
115 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.